Clinical Trial Update: Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates combining irinotecan with dual EGFR/HER2 blockade for HER2-positive metastatic colorectal cancer; the study status is not yet recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Irinotecan (Irinotecan)

Snippet

Sponsor: Sun Yat-sen University | Conditions: HER2 Positive, Colorectal Cancer (CRC) | Phase 2 | Status: NOT_YET_RECRUITING